A 36-year-old woman with recurrent high-grade fevers, hypotension, and hypertriglyceridemia

Arthritis Care and Research

Volumn 62, Issue 1, 2010, Pages 128-136

  Chou, Richard C ^a   Dinarello, Charles A ^c   Ferry, Judith A ^b   Cin, Paola Dal ^d  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; BROMOCRIPTINE; COLCHICINE; COTRIMOXAZOLE; CREATINE KINASE; CYCLOSPORIN; ETANERCEPT; FERRITIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRIACYLGLYCEROL;

ADULT; ADULT ONSET STILL DISEASE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AUTOINFLAMMATORY DISEASE; BONE MARROW BIOPSY; CASE REPORT; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DERMATOMYOSITIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; HYPOTENSION; LEG EDEMA; LEUKOCYTOSIS; MACROPHAGE ACTIVATION SYNDROME; MUSCLE BIOPSY; MYELODYSPLASTIC SYNDROME; MYOSITIS; NEUROLEPTIC MALIGNANT SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT FEVER; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION;

ADULT; DIAGNOSIS, DIFFERENTIAL; FEMALE; FEVER; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOTENSION; MACROPHAGE ACTIVATION SYNDROME; PATIENT ADMISSION; RECURRENCE;

EID: 74549215677     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20024     Document Type: Conference Paper

References (36)

1. Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 2006;65:564-72.
2. Fitzgerald AA, LeClercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794-803.
3. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005;146:598-604.
4. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002;14:548-52.
5. Emmenegger U, Schaer DJ, Larroche C, Neftel KA. Haemophagocytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly 2005;135:299-314.
6. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005;7:R30-7.
7. Maeno N, Takei S, Imanaka H, Yamamoto K, Kuriwaki K, Kawano Y, et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum 2004;50:1935-8.
8. Esfandiari E, McInnes IB, Lindop G, Huang FP, Field M, Komai-Koma M, et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J Immunol 2001;7:5338-47.
9. Leung BP, Culshaw S, Gracie JA, Hunter D, Canetti CA, Campbell C, et al. A role for IL-18 in neutrophil activation. J Immunol 2001;167:2879-86.
10. McInnes IB, Gracie JA, Liew FY. Interleukin-18: a novel cytokine in inflammatory rheumatic disease. Arthritis Rheum 2001;44:1481-3.
11. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6.
12. Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology (Oxford) 2001;40:1285-92.
13. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996;129:750-4.
14. Ravelli A, Viola S, de Benedetti F, Magni-Manzoni S, Tzialla C, Martini A. Dramatic efficacy of cyclosporine A in macrophage activation syndrome. Clin Exp Rheumatol 2001;19:108.
15. You CR, Kim HR, Yoon CH, Lee SH, Park SH, Kim HY. Macrophage activation syndrome in juvenile rheumatoid arthritis successfully treated with cyclosporine A: a case report. J Kor Med Sci 2001;21:1124-7.
16. Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E. The Schnitzler syndrome: four new cases and review of the literature. Medicine (Baltimore) 2001;80:37-44.
17. De Koning HD, Bodar EJ, van der Meer JW, Simon A, and the Schnitzler Syndrome Study Group. Schnitzler syndrome: beyond the case reports. Review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007;37:137-48.
18. Ryan JG, de Koning HD, Beck LA, Booty MG, Kastner DL, Simon A. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 2008;121:260-2.
19. Frischmeyer-Guerrerio PA, Rachamalla R, Saini SS. Remission of Schnitzler syndrome after treatment with anakinra. Ann Allergy Asthma Immunol 2008;100:617-9.
20. Dybowski F, Sepp N, Bergerhausen HJ, Braun J. Successful use of anakinra to treat refractory Schnitzler's syndrome. Clin Exp Rheumatol 2008;26:354-7.
21. Samuels J, Ozen S. Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol 2006;18:108-17.
22. Masters SL, Lobito AA, Chae J, Kastner DL. Recent advances in the molecular pathogenesis of hereditary recurrent fevers. Curr Opin Allergy Clin Immunol 2006;6:428-33.
23. Stevens-Kroef M, Poppe B, van Zelderen-Bhola S, van den Berg E, van der Blij-Philipsen M, Geurts van Kessel A, et al. Translocation t(2;3)(p15-23;q26- 27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. Leukemia 2004;18:1108-14.
24. Shadduck RK, Latsko JM, Rossetti JM, Haq B, Abdulhaq H. Recent advances in myelodysplastic syndromes. Exp Hematol 2007;35:137-43.
25. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007;7:118-29.
26. Tiu R, Gondek L, O'Keefe C, Maciejewski JP. Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia 2007;21:1648-57.
27. Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG. Myelodysplasia- associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest 2004;4:690-700.
28. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002;99:1594-601.
29. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005;166:557-63.
30. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001;98:3058-65.
31. Reza S, Dar S, Andric T, Qawi H, Mundle S, Shetty V, et al. Biologic characteristics of 164 patients with myelodysplastic syndromes. Leuk Lymphoma 1999;33:281-7.
32. Kobayashi K, Yokote T, Akioka T, Hara S, Hiraoka N, Oka S, et al. Granulocyte colony-stimulating factor and interleukin-6 production by myelodysplastic syndrome blasts. Leuk Lymphoma 2008;49:589-91.
33. Marcondes AM, Mhyre AJ, Stirewalt DL, Kim SH, Dinarello CA, Deeg HJ. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Nat Acad Sci U S A 2008;105:2865-70.
34. Takubo T, Kumura T, Nakao T, Nakamae H, Aoyama Y, Nishiki S, et al. Clinical usefulness of combined measurements of serum soluble transferrin receptor levels and serum interleukin-18 levels at determination of serum KL-6 levels in haematologic malignancies. Acta Haematol 2000;104:141-3.
35. Giannouli S, Tzoanopoulos D, Ritis K, Kartalis G, Moutsopoulos HM, Voulgarelis M. Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. Ann Rheum Dis 2004;63:578-82.
36. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Ann Rev Med 2005;56:1-16.